The latest oncology investment report is out, below is a look at all the money that moved across the drug development industry in the US and EU. Each report includes a look at Seed to Series E, IPO and Debt Financing. This gives a good idea of where money is moving to and from. The report is completely free - all I ask is, if you did receive value, please share this or my work with others. Thank you!
Click here to download your free report or the link at the bottom.
Biggest Seed, Series A-E and Venture Investments within USA Oncology September 2023.
Here are some important companies to follow over the next 12 months.
✅ Innovac Therapeutics - $18,000,000 (Seed) : mRNA Cancer vaccines, pre-clinical stage
✅ Deka Biosciences - $20,000,000 (Series B) : EGFR Approach, 1x Phase I and mostly preclinical
✅ Rome Therapeutics - $72,000,000 (Series B) : Reverse Transcriptase / Viral Mimicry. Preclinical.
✅ Generate Biomedicines - $273,000,000 (Series C) : Ai Drug Development - Preclinical Oncology.
✅ Rakuten Medical - $104,816,348 (Venture) : Photoactivated Immunotherapy (Phase I - III)
✅ Noetik - $14,000,000 (Seed) : Ai Generated Precision Medicine. Preclinical.
✅ Plus 25+ more in the report
Click here to view the full report.
